No Data
No Data
No Data
Regent Pacific (00575.HK): Signed licensing agreement with Kobayashi for commercial sale of Fortacin in Japan.
Regent Pacific (00575.HK) announced on July 26 that on July 26, 2024, Plethora (a wholly owned subsidiary of the company) and Kobayashi (a company registered in Japan) entered into a license agreement regarding the commercial rights to commercialize the latest pharmaceutical Fortacin for the treatment of premature ejaculation by Plethora in Japan through sales and distribution of Fortacin (including other methods). Plethora continues to retain commercial rights in other parts of the world, including but not limited to the USA, Canada, Latin America, the Middle East, and Sub-Saharan Africa.
Regent Pacific (00575) has entered into a licensing agreement with KOBAYASHI for FORTACIN commercial sales in Japan.
Regent Pacific (00575) announced that on July 26, 2024 (after the Hong Kong Stock Market closes), Pleth ...
Express News | Regent Pacific - Under Licence Agreement, Co Will Be Eligible to Receive Payments of up to US$1.55 Mln
Express News | Regent Pacific Group - Licence Agreement With Kobayashi for Commercial Launch of Fortacin™ in Japan
Regent Pacific Group Expects Narrower Attributable Loss in H1 2024
Regent Pacific (00575.HK) is expected to report a net loss of 2.5 to 3.5 million US dollars in the first half, with a significant decrease in year-on-year losses.
Regent Pacific (00575.HK) announced on July 25th that the group expects to record a loss of approximately 2.5 million US dollars (or approximately 19.5 million Hong Kong dollars) to 3.5 million US dollars (or approximately 27.3 million Hong Kong dollars) attributable to equity holders of the Company for the six months ending on June 30, 2024 (the"reporting period"), reflecting a significant reduction in losses compared to the six months ending on June 30, 2023 (the "corresponding period") when equity holders of the Company recorded a loss of approximately 12.2 million US dollars (or approximately 95.16 million Hong Kong dollars). The above-mentioned unaudited interim performance for the reporting period is compared to the corresponding period.
No Data